Clinical Trials Network Division
Research Areas - Studies in Progress
CTN 0037 Stimulant Reduction Intervention using Dosed Exercise(STRIDE)
Primary Aim: To test the effectiveness of regular dosed exercise to see if it improves outcomes for treatment of persons with cocaine, amphetamine or other substance use diosorders.
Study Site: Penn Presbyterian Medical Center, 3910 Powelton Avenue, Philadelphia, PA 19104
Study Physician: Regina Szucs Reed, M.D.
CTN 0050: START Follow-up Study. This is a follow-up study of Starting Treatment with Agonist Replacement Studies, (START) CTN 0027 of the NIDA Clinical Trials Network.
Primary Aims: To determine long-term outcomes of Suboxone treatment versus methadone treatment received in the START Study; To investigate study participant and treatment factors associated with post-START treatment access, utilization, and outcomes among Suboxone participants and methadone participants; To explore other correlates of long-term outcomes among START study participants.
Study Site: NETSteps, 2205 Bridge Street, Philadelphia, PA 19137
Site PI: John T. Carroll, CAC
CTN 0049: Project HOPE – Hospital Visit as Opportunity for Prevention and Engagement for HIV-infected Drug Users
Primary Aim: To evaluate the effectiveness of Patient Navigator and Contingency Management in achieving suppression of HIV viral load among substance using hospitalized HIV-infected individuals with initially unsuppressed HIV viral load.
Study Site: Division of ID & HIV Medicine, Drexel University College of Medicine, New College Building 6th Fl, Room 6314, 245 N 15th Street MS 461, Philadelphia, PA 19102
Site PI: Jeffrey Jacobson, M.D.
CTN 0052: Buspirone for Relapse-Prevention in Adults with Cocaine Dependence (BRAC)
Primary Aim: To evaluate the efficacy of buspirone, relative to placebo, in preventing relapse in cocaine-dependent adults in inpatient/residential treatment who are planning to enter outpatient treatment upon inpatient/residential discharge. Secondary objectives include evaluating the impact of buspirone, relative to placebo, on other drug-abuse outcomes and on factors that may mediate buspirone's efficacy as a relapse-prevention treatment.
Study Site: Penn Presbyterian Medical Center, 3910 Powelton Avenue, Philadelphia, PA 19104
Site PI: Kyle Kampman, M.D., Treatment Research Center, University of Pennsylvania
Back to Top